Table 1 Characteristics of studies included in meta-analysis.

From: Predictive assessment in pharmacogenetics of Glutathione S-transferases genes on efficacy of platinum-based chemotherapy in non-small cell lung cancer patients

Author	Year	Country	Ethnicity	Patients numbers	Age (year)	Smoking	Clinical stage	Evaluation criterion	Outcomes	Genotyping method	Genes	QS
L. Bu et al.¹⁹	2016	China	Asian	141	55.95 ± 7.83	65.96%	III-IV	RECIST	ORR/OS	PCR-RFLP	GSTP1	14
Jia W. et al.²⁰	2016	China	Asian	265	57.50 ± 11.25	44.26%	IIIA, IIIB, IV.	RECIST	ORR/OS	PCR-RFLP	GSTP1, GSTM1, GSTT1	15
Chen J.B. et al.²¹	2016	China	Asian	284	63.60 ± 11.65	60.21%	IIIA, IIIB, IV.	RECIST	OS/PFS	DNA pyrosequencing	GSTP1, GSTM1, GSTT1	22
Xiao H.L. et al.²²	2016	China	Asian	262	58.42 ± 8.50	64.12%	IIIA, IIIB, IV	RECIST	ORR/OS/MST	PCR-RFLP	GSTP1, GSTM1, GSTT1	18
Liu K. et al.²³	2015	China	Asian	308	66.12 ± 10.32	62.98%	IIIA, IIIB, IV	RECIST	ORR/OS	PCR-RFLP	GSTP1, GSTM1, GSTT1	15
Zhao R. et al.²⁴	2015	China	Asian	206	56.07 ± 8.85	65.53%	III-IV	RECIST	ORR/OS/MST	PCR-RFLP	GSTP1	18
Wu G. et al.²⁵	2015	China	Asian	282	59.15 ± 10.50	68.44%	IIIA, IIIB, IV	RECIST	ORR/OS	PCR-RFLP	GSTP1, GSTM1, GSTT1	15
Liu J.Y. et al.²⁶	2015	China	Asian	322	62.5 ± 9.5	43.48%	IIIB, IV	RECIST	ORR/OS	PCR-RFLP	GSTP1	16
Han B. et al.²⁷	2015	China	Asian	325	57.6 ± 12.4	68.31%	IIIB, IV	RECIST	ORR/OS/MST	PCR-RFLP	GSTP1	19
Deng J.H. et al.¹⁶	2015	China	Asian	97	NR	40.20%	IIIB, IV	RECIST	ORR/DCR/PFS	DNA pyrosequencing	GSTP1	15
Yuan Z.J. et al.²⁸	2015	China	Asian	47	NR	NR	III-IV	RECIST	ORR	Sanger sequencing	GSTP1	13
Li Q.Y. et al.⁵⁷	2014	China	Asian	89	60.73 ± 10.857	NR	III-IV	RECIST	ORR	Direct sequencing	GSTP1, GSTM1	12
Lv H. et al.²⁹	2014	China	Asian	91	59 (34–80)	NR	III-IV	WHO	ORR/Medium TTP	TaqMan-MGB	GSTP1	15
Ruano-Ravina A. et al.³⁷	2014	Spain	Caucasian	132	66 (38–87)	NR	I-IV	NR	OS/MST	PCR-RFLP	GSTP1, GSTM1, GSTT1	14
Li W. et al.³⁸	2012	China	Asian	217	58.98 (24–83)	55.80%	III-IV	NR	ORR/OS	PCR-RFLP	GSTM1	12
Ke H.G. et al.³⁰	2012	China	Asian	460	55 (32–79)	67.30%	III-IV	NR	OS	PCR- CTPP	GSTP1	14
Zhang Y.P. et al.⁵⁸	2012	China	Asian	62	58 (37–72)	NR	III-IV	RECIST	ORR	TaqMan PCR	GSTP1	15
Joerger M. et al.³¹	2012	Switzerland	Caucasian	146	59.7 (37–79)	83%	IIIB/IV	RECIST	ORR/OS/PFS	DNA sequencing	GSTP1, GSTM1	20
Zhou F. et al.⁵⁹	2011	China	Asian	94	NR	NR	IIIB, IV	RECIST	ORR	Direct sequencing	GSTP1	12
Zhou Fei et al.¹⁴	2011	China	Asian	111	57 (42–71)	NR	IV	RECIST	TPP/ORR	DNA sequencing	GSTP1	16
Sun N. et al.³³	2010	China	Asian	113	59.6 (34–84)	NR	IIIA–IV	WHO	ORR	Gene-chip	GSTP1	16
Ada A.O. et al.³²	2010	Turkey	Caucasian	138	56 (34–75)	90.60%	III, IV	WHO	OS	PCR-RFLP	GSTP1, GSTM1, GSTT1	15
Yue Z. et al.⁶⁰	2009	China	Asian	102	61 (27–78)	NR	III-IV	WHO	ORR	PCR-RFLP	GSTP1	13
Kalikaki A. et al.³⁴	2009	Greece	Caucasian	119	61 (39–85)	NR	IIIA, IIIB, IV	RECIST	ORR/OS/MST	PCR-RFLP	GSTP1, GSTM1, GSTT1	17
Li W. et al.³⁹	2008	China	Asian	141	—	56%	III-IV	RECIST	ORR	PCR-RFLP	GSTP1, GSTM1	11
Sreeja L. et al.⁴⁹	2008	India	Caucasian	211	57.82 ± 11.74	68.20%	I-IV	NR	OS	Multiplex PCR	GSTP1, GSTM1, GSTT1	12
Mao Y. et al.⁶¹	2007	China	Asian	59	45 (18–65)	NR	IIIB, IV	NR	ORR	PCR-LDR	GSTP1, GSTM1	10
Gonlugur U. et al.⁶²	2006	Turkey	Caucasian	81	60 (40–78)	88%	I-IV	NR	OS	PCR-RFLP	GSTM1, GSTT1	10
Booton R. et al.³⁵	2006	United Kingdom	Caucasian	108	NR	NR	III-IV	RECIST	ORR/OS/MST	Direct sequencing	GSTP1	19
Lu C. et al.³⁶	2006	USA	Caucasian	425	NR	89.60%	III, IV	RECIST	OS	PCR-RFLP	GSTP1	15
Sweeney C. et al.¹⁵	2003	USA	Caucasian	274	62 (28–74)	NR	III-IV	NR	OS	PCR-RFLP	GSTP1, GSTM1, GSTT1	12

NR: not reported; QS, quality score; HR: hazard ratio; ORR: objective response rate; OS, overall survival (months); PFS, progression-free survival (months); MST, median survival time (months); TTP, time to progression (months); PCR, polymerase chain reaction; PCR-RFLP, PCR-restriction fragment length polymorphism; RECIST, Response Evaluation Criteria in Solid Tumors; WHO, World Health Organization; PCR-LDR, PCR-ligase detection reaction; PCR-CTPP, duplex PCR with the confronting-two-pair primer; Sequenome MS-based genotyping assay, sequenome mass spectrometry-based genotyping assay; PCR-CTTP, PCR with confronting two-pair primers.

Back to article page

Table 1 Characteristics of studies included in meta-analysis.

Search

Quick links